A carregar...
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine in some countries) were approved in the US to improve walking in patients with multiple sclerosis, as demonstrated by improvement in walking speed. Postmarketing safety experie...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3647381/ https://ncbi.nlm.nih.gov/pubmed/23662056 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S41596 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|